Page 74 nursing.elitecme.com Complete Your CE Test Online - Click Here 77. Coste J, Cochand-Priollet B, de Cremoux P, et al. (2003). Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. British Medical Journal, 326(7392): 733. 78. CredibleMeds (2016). Risk Categories for Drugs that Prolong QT & induce Torsades de Pointes (TdP). Retrieved from https://crediblemeds.org/new-drug-list/ on April 8, 2016. 79. Cusack G (2014). Vascular Access Devices. In MM Gullatte (Ed.) Clinical Guide to Antineoplastic Therapy: A chemotherapy handbook, 3rd ed. Pittsburgh, PA: Oncology Nursing Society pp 709–755. 80. de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK (2014). The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer, 120(20): 3245-3253. 81. Dean L. Tamoxifen Therapy and CYP2D6 Genotype. Bethesda (MD) In: Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US); 2012. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK247013/ on April 4, 2016. 82. Domchek SM, Friebel TM, Singer CF, et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Journal of the American Medical Association, 304(9): 967–975. 83. Eggert J. Pharmacogenomics and Chemotherapy (2014). In MM Gullatte (Ed.) Clinical Guide to Antineoplastic Therapy: A chemotherapy handbook, 3rd ed. Pittsburgh, PA: Oncology Nursing Society. pp. 939-968. 84. Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK (2012). Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: A systematic review and meta-analysis of randomized controlled trials. Public Library of Science Medicine, 9(12): e1001352. 85. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. (2011). Spectrum of cancer risk among US solid organ transplant recipients. Journal of the American Medical Association, 306(17): 1891-1901. 86. English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL (1998). Case-control study of sun exposure and squamous cell carcinoma of the skin. International Journal of Cancer, 77(3): 347-353 87. EpiGenomics. 2014. Physician Messaging and Brochure Content [Epi proColon]. Retrieved from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/ UCM390239.pdf on April 14, 2016. 88. Esserman LJ, Thompson IM, Reid B, et al. (2014). Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology,15(6): e234-242. 89. Fazel R, Krumholz HM, Wang Y, et al. (2009). Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 361(9): 849-57. 90. Ferrone CR, Levine DA, Tang LH, et al. (2009). BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of Clinical Oncology, 27(3): 433–438. 91. Finch AP, Lubinski J, Møller P, et al. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15): 1547-1553. 92. Flockhart DA (2015). Cytochrome P450 Drug Interaction: Abbreviated “Clinically Relevant” Table. Indiana University School of Medicine. Retrieved from http://medicine.iupui.edu/clinpharm/ddis/ clinical-table on March 21, 2016. 93. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF (2013). Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer, 41(1): 45-60. 94. Gilmore TR, Schulmeister L, Jacobson JO (2013). Quality Oncology Practice Initiative Certification Program: measuring implementation of chemotherapy administration safety standards in the outpatient oncology setting. Journal of Oncology Practice, 9(2 Suppl): 14s-8s. 95. Greenlaw E (2011). What is Carcinoid Syndrome? Retrieved from http://www.webmd.com/cancer/ features/what-is-carcinoid-syndrome on March 8, 2016. 96. Gronwald J, Tung N, Foulkes WD, et al. (2006). Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. International Journal of Cancer, 118(9): 2281–2284. 97. Health Physics Society (2015). Therapy-Nuclear Medicine. Retrieved from http://hps.org/ publicinformation/ate/faqs/nuclearmedicinetherapy.html on April 7, 2016. 98. Henley SJ, Thun MJ, Chao A, Calle EE (2004). Association Between Exclusive Pipe Smoking and Mortality from Cancer and Other Diseases. Journal of the National Cancer Institute, 96(11), 853-861. 99. Henry R (2015). Infectious Diseases related to travel. Retrieved from http://wwwnc.cdc.gov/travel/ yellowbook/2016/infectious-diseases-related-to-travel/helicobacter-pylori on March 29, 2016. 100. Hensley ML, Hagerty KL, Kewalramani T, et al. (2009). American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol, 27(1): 127-45. 101. Hershman DL, Lacchetti C, Dworkin RH, et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 20;32(18): 1941-1967. 102. Holland JC, Lewis S (2000) The Human Side of Cancer, Living with Hope, Coping with Uncertainty. New York, HarperCollins. ISBN: 0-06-017371-8. 103. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, Retrieved from http://seer.cancer.gov/csr/1975_2011/. Retrieved from http://seer.cancer.gov/archive/csr/1975_2011/ on April 13, 2016. 104. Holowaty P, Miller AB, Rohan T, To T (1999). Natural history of dysplasia of the uterine cervix. Journal of the National Cancer Institute, 91(3): 252-258. 105. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG (2013) Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Annals of Internal Medicine, 159(6): 411-420. 106. International Agency for Research on Cancer (2015). Agents Classified by the IARC Monographs, Volumes 1 – 114. 2015. Retrieved from http://monographs.iarc.fr/ENG/Classification/latest_classif. php on March 17, 2016. 107. International Agency for Research on Cancer (2015). IARC Monographs Volume 112: evaluation of five organophosphate insecticides and herbicides. Retrieved from https://www.iarc.fr/en/media- centre/iarcnews/pdf/MonographVolume112.pdf on April 13, 2016. 108. International Agency for Research on Cancer (1986). International Agency for Research on Cancer Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. British Medical Journal (Clinical research Edition), 293(6548): 659-664. 109. International Agency for Research on Cancer (2007). Smokeless Tobacco and Some Tobacco- Specific N-Nitrosamines. Lyon, France: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 89. 110. Kehrer DF, Sparreboom A, Verweij J, et al. (2001). Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clinical Cancer Research, 7(5), 1136-1141. 111. King MC, Wieand S, Hale K, et al. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP–P1) Breast Cancer Prevention Trial. Journal of the American Medical Association, 286(18): 2251–2256. 112. Kleinman JC, Kopstein A (1981). Who is being screened for cervical cancer? American Journal of Public Health, 71(1): 73-76. 113. Koh HK (1991). Cutaneous melanoma. New England Journal of Medicine, 325(3): 171-182. 114. Krumm S, Garrett MR, Bowles KA (2014). Legal Issues in Cancer Care. In MM Gullatte (Ed). Clinical Guide to Antineoplastic Therapy: A chemotherapy handbook, 3rd ed. Pittsburgh, PA: Oncology Nursing Society. pp. 687-708. 115. Kushi LH, Doyle C, McCullough M, et al. (2012). American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention. CA: A Cancer Journal for Clinicians, 62(1): 30–67. 116. Kuter DJ (2015). Managing Thrombocytopenia Associated with Cancer Chemotherapy. Oncology Journal. Retrieved from http://www.cancernetwork.com/oncology-journal/managing- thrombocytopenia-associated-cancer-chemotherapy/page/0/4 on April 9, 2016. 117. Lauterstein D, Hoshino R, Gordon T, Watkins BX, Weitzman M, Zelikoff J (2014). The Changing Face of Tobacco Use Among United States Youth. Current Drug Abuse Reviews, 7(1), 29–43. 118. Lennes IT, Bohlen N, Park ER, Mort E, Burke D, Ryan DP (2016). Chemotherapy Errors: A Call for a Standardized Approach to Measurement and Reporting. Journal of Oncology Practice, doi:10.1200/JOP.2015.008995 (published online before print.) 119. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, Schulman J (2006) Complications of colonoscopy in an integrated health care delivery system. Annals of Internal Medicine, 145(12): 880-886. 120. Levy-Lahad E, Friedman E (2007). Cancer risks among BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 96(1): 11–15. 121. Lichtenfeld L (2010). CT Screening for Lung Cancer: Caution Ahead. Retrieved from http://blogs. cancer.org/drlen/2010/04/20/ct-screening-for-lung-cancer-caution-ahead/?_ga=1.200835117.202323 5592.1456268404 on March 7, 2016. 122. Lichtenfeld L (2015). New Research on Dictal Carcinoma in Situ (DCIS) Bring Knowledge – Now We Need Understanding. Retrieved from http://blogs.cancer.org/drlen/2015/08/21/new-research-on- ductal-carcinoma-in-situ-dcis-brings-knowledge-now-we-need-understanding/?_ga=1.198430124.20 23235592.1456268404 on March 7, 2016. 123. Mathews JD, Forsythe AV, Brady Z, et al. (2013). Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. British Medical Journal, 346: f2360. 124. Mayo Clinic (n.d.). Radiation Therapy. Retrieved from http://www.mayoclinic.org/tests-procedures/ radiation-therapy/basics/risks/prc-20014327 on April 5, 2016. 125. McCann J (2000). Gender differences in cancer that don’t make sense--or do they? Journal of the National Cancer Institute, 92(19): 1560-1562. 126. McCallum PD, Polisena CG, (Eds) (2000). The Clinical Guide to Oncology Nutrition. Chicago, IL: The American Dietetic Association. 127. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC (2008). Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology, 9(5): 425-434. 128. McLaughlin JR, Risch HA, Lubinski J, et al. (2007). Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncology, 8(1): 26–34. 129. Memorial Sloan Kettering Cancer Center. (n.d.) Skin Care Guidelines for Patients Receiving Radiation Therapy. Retrieved from https://www.mskcc.org/cancer-care/patient-education/skin-care- guidelines-patients-receiving-radiation-therapy on April 5, 2016. 130. Merskey H, Bogduk N, eds. (1994). Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, Wash: IASP Press. Retrieved from http://www.iasp-pain.org/files/Content/ContentFolders/Publications2/FreeBooks/Classification-of- Chronic-Pain.pdf on April 15, 2016. 131. Mettler FA, Huda W, Yoshizumi TT, Mahesh M. (2008). Effective Doses in Radiology and Diagnostic Nuclear Medicine: A Catalog. Radiology. 2008 Jul;248(1):254-263. doi: 10.1148/ radiol.2481071451. Retrieved from http://pubs.rsna.org/doi/full/10.1148/radiol.2481071451 on April 4, 2016. 132. Mettler FA Jr, Thomadsen BR, Bhargavan M, et al. (2008). Medical radiation exposure in the U.S. in 2006: preliminary results. Health Physics, 95(5): 502-507. 133. Moore HC (2014). An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park), 28(9): 797-804. 134. Mulcahy N (2013) NCI Panel: Stop Calling Low-Risk Lesions ‘Cancer’: New Proposals to Reduce Overdiagnosis. Medscape Medical News, Oncology. Retrieved from http://www.medscape.com/ viewarticle/808654#vp_1 on March 4, 2016. 135. National Aeronautics and Space Administration (2014). Introduction to the Electromagnetic Spectrum. Retrieved from http://missionscience.nasa.gov/ems/01_intro.html on March 17, 2016. 136. National Aeronautics and Space Administration (2014). Ultraviolet Waves. Retrieved from http:// missionscience.nasa.gov/ems/10_ultravioletwaves.html on March 17, 2016. 137. National Cancer Institute (2015). Age. Retrieved from http://www.cancer.gov/about-cancer/causes- prevention/risk/age on March 18, 2016. 139. National Cancer Institute (2013). Alcohol and Cancer Risk. Retrieved from http://www.cancer.gov/ about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet on March 29, 2016. 140. National Cancer Institute (2015). BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Retrieved from http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet on March 14, 2016. 141. National Cancer Institute (2015). Breast Cancer Prevention – Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/types/breast/hp/breast-prevention-pdq#link/_184_toc on April 13, 2016. 142. National Cancer Institute (2016). Breast Cancer Screening–Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/types/breast/hp/breast-screening-pdq on March 8, 2016. 143. National Cancer Institute (2014). Breast Cancer Treatment and Pregnancy--Health Professional Version (PDQ®) Retrieved from http://www.cancer.gov/types/breast/hp/pregnancy-breast-treatment- pdq on May 16, 2016. 144. National Cancer Institute (2015). Cancer – Causing Substances in the Environment. Retrieved from http://www.cancer.gov/about-cancer/causes-prevention/risk/substances on March 18, 2016. 145. National Cancer Institute (2016). Cancer Pain – Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq#section/all on April 14, 2016. 146. National Cancer Institute (2016). Cancer Pain – Patient Version (PDQ®). Retrieved from http:// www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-pdq#section/all on April 14, 2016. 147. National Cancer Institute (2016). Cancer Prevention – Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/types/skin/hp/skin-prevention-pdq on March 29, 2016. 148. National Cancer Institute (2016). Cancer Prevention Overview–Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/about-cancer/causes-prevention/hp-prevention- overview-pdq on March 29, 2016. 149. National Cancer Institute (2015). Cancer Screening. Retrieved from http://www.cancer.gov/about- cancer/screening on March 4, 2016. 150. National Cancer Institute (2016.) Cervical Cancer Screening – Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/types/cervical/hp/cervical-screening-pdq on March 9, 2016. 151. National Cancer Institute (2016.) Cervical Cancer Treatment – Health Professional Version (PDQ®). Retrieved from http://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq#section/_798 on April 5, 2016. 152. National Cancer Institute (2015). Chemotherapy. Retrieved from http://www.cancer.gov/about- cancer/treatment/types/chemotherapy on April 1, 2016. 153. National Cancer Institute (2010). Chemotherapy-Induced Peripheral Neuropathy. Retrieved from http://www.cancer.gov/about-cancer/treatment/research/peripheral-neuropathy on April 10, 2016.